Research ArticleAutism

Negative Allosteric Modulation of the mGluR5 Receptor Reduces Repetitive Behaviors and Rescues Social Deficits in Mouse Models of Autism

See allHide authors and affiliations

Science Translational Medicine  25 Apr 2012:
Vol. 4, Issue 131, pp. 131ra51
DOI: 10.1126/scitranslmed.3003501

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Treatment of Autism Symptoms in Mice

When they are 2 to 5 years old, children with autism start to show unusual social interactions and impaired communication. They may fail to develop relationships with their peers and be unable to interpret nuances of speech and body language. Most show repetitive motor behaviors and restricted interests and can have associated seizures, anxiety, or intellectual impairment. A large number of genes can put people at risk for this disorder, each in a small number of cases, and these genes point to connections between neurons as a vulnerable point in autism. Now, Silverman and colleagues have used two inbred strains of mice that display well-replicated behavioral abnormalities relevant to the diagnostic symptoms of autism and shown that some of these symptoms can be improved with a drug directed at a central glutamate receptor of the brain, mGluR5.

The authors used two inbred strains of mice that display robust behaviors relevant to the diagnostic symptoms of autism. BTBR mice show deficits in many types of social interactions and high levels of repetitive self-grooming. C58 repetitively jumps. They used GRN-529, a compound developed by Pfizer that reduces the actions of glutamate, the main excitatory neurotransmitter in the brain. Other mGluR antagonists are showing promise in clinical trials for people with the fragile X mutation, who have both intellectual impairments and autism, so the authors reasoned that an mGluR5 compound might help autistic symptoms.

GRN-529 reduced both the repetitive self-grooming in BTBR and the repetitive jumping in C58. Most intriguingly, GRN-529 also improved social behaviors in BTBR in two assays, one for social approach to an unfamiliar mouse and one for social interactions between freely moving pairs of mice. A particular strength of this study is that the authors replicated these beneficial actions of the mGluR5 compound in several separate groups of mice, in two laboratories.

Although the path from target identification to effective human treatment is a long and winding road, the discovery of therapeutic efficacy for an mGluR5 negative allosteric modulator in both the repetitive and the social domains in two distinct mouse models is a promising beginning. This single biological target may offer a useful entry point to develop a pharmacological therapy that alleviates many symptoms of autism spectrum disorders.

View Full Text

Stay Connected to Science Translational Medicine